Curley Steven A
The University of Texas M. D. Anderson Cancer Center, Department of Surgical Oncology, Box 444, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA.
Ann Surg Oncol. 2003 May;10(4):338-47. doi: 10.1245/aso.2003.07.017.
Radiofrequency ablation (RFA) is being used to treat primary and metastatic liver tumors. The indications, treatment planning, and limitations of hepatic RFA must be defined and refined by surgeons treating hepatic malignancies.
A review of the experience using RFA to treat unresectable primary and secondary hepatic malignancies at the University of Texas M. D. Anderson Cancer Center in Houston, Texas, and the G. Pascale National Cancer Institute in Naples, Italy, is provided. Patient selection, treatment approach, local recurrence rates, and overall cancer recurrence rates following RFA are described. The current literature on RFA of hepatic malignancies is reviewed.
RFA of hepatic tumors can be performed percutaneously, laparoscopically, or during an open surgical procedure. Incomplete treatment manifest as local recurrence is more common with a percutaneous approach. The morbidity and mortality rates associated with hepatic RFA are low. Local recurrence rates are low if meticulous treatment planning is performed. RFA can be combined safely with partial hepatic resection of large lesions. The long-term survival rates following RFA of primary and metastatic liver tumors have not yet been established.
RFA of hepatic malignancies is a safe and promising technique to produce coagulative necrosis of unresectable hepatic malignancies. Experience with this treatment modality is not yet mature enough to establish long-term outcomes.
射频消融（RFA）正被用于治疗原发性和转移性肝肿瘤。肝RFA的适应证、治疗规划及局限性必须由治疗肝脏恶性肿瘤的外科医生来明确和完善。
本文回顾了德克萨斯大学MD安德森癌症中心（位于得克萨斯州休斯顿）以及意大利那不勒斯的帕斯卡尔国家癌症研究所使用RFA治疗不可切除的原发性和继发性肝脏恶性肿瘤的经验。描述了患者选择、治疗方法、RFA后的局部复发率及总体癌症复发率。对目前有关肝脏恶性肿瘤RFA的文献进行了综述。
肝脏肿瘤的RFA可经皮、腹腔镜或在开放手术过程中进行。经皮途径更易出现表现为局部复发的治疗不彻底情况。与肝脏RFA相关的发病率和死亡率较低。如果进行细致的治疗规划，局部复发率较低。RFA可安全地与大病灶的肝部分切除术联合应用。原发性和转移性肝肿瘤RFA后的长期生存率尚未确定。
肝脏恶性肿瘤的RFA是一种安全且有前景的技术，可使不可切除的肝脏恶性肿瘤产生凝固性坏死。这种治疗方式的经验尚不够成熟，无法确定长期疗效。
